Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 17;12:589273. doi: 10.3389/fphar.2021.589273

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Li, Li, Huang, Han, Tan, An, Xiang, Zhou, Yang and Cheng.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Dapagliflozin improves glucose intolerance and regulates lipid metabolism in ZDF rats. (A) Body weight was recorded every week and body weight gain was measured at the end of the 21st week. (B) Blood glucose levels were monitored throughout the entire experiment. (C) The area under the curve (AUC) of blood glucose was calculated by the trapezoidal method. (D) Serum insulin levels were evaluated in groups. (E–H) Serum levels of TG, TC, LDL-C, and HDL-C were evaluated in groups. ZL: ZL rats as a normal control, ZDF: ZDF rats fed with a high-fat diet, ZDF + Dapa: dapagliflozin-treated ZDF rats. Data are expressed as the means ± SEM of five animals per group. *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the ZDF rat group.